AstraZeneca

Enhertu tops standard care in first-line HER2 lung cancer trial

AstraZeneca and Daiichi Sankyo announced on Monday that their antibody drug conjugate Enhertu demonstrated a statistically significant improvement in progression-free survival over the current global standard of care as a first-line treatment for patients with HER2-mutant advanced lung cancer, marking…

AstraZeneca-Bristol Myers merger talks denied by senior source

Days of feverish speculation over a potential $400 billion pharmaceutical mega merger came to an abrupt end on Wednesday when a senior source close to the matter told Reuters that there are "no discussions" between AstraZeneca and Bristol Myers Squibb…

AstraZeneca shares tumble on reported Bristol Myers merger talks

AstraZeneca shares tumbled approximately 7% in early London trading on Monday after reports that the British pharmaceutical giant had held preliminary discussions with Bristol Myers Squibb Bristol-Myers Squibb Company about a potential merger that would create one of the world's…

AstraZeneca in merger talks with Bristol Myers Squibb, FT reports

AstraZeneca has been exploring a deal to combine with Bristol Myers Squibb Bristol-Myers Squibb Company, the Financial Times News Corp reported on Sunday, citing people familiar with the matter. The potential combination, valued at nearly $400 billion, would rank among…

AstraZeneca says MFN policy changed its drug launch pricing

AstraZeneca disclosed on Monday that it has shifted its pricing approach for new drug launches in response to the Trump administration's most-favored-nation policy, as the company reported second-quarter earnings that beat profit expectations.

Oil retreats, markets stabilize as Trump says Iran wants to negotiate

Global markets began to recover on Thursday as oil prices pulled back from their midweek highs and reports emerged that Iran had signaled willingness to resume negotiations with the United States, offering investors a partial reprieve after days of escalating…

AstraZeneca, GSK strike deals with Sino Biopharma amid U.S. scrutiny

AstraZeneca and GSK announced separate partnerships with China's Sino Biopharmaceutical on Wednesday, marking a flurry of cross-border pharmaceutical dealmaking even as U.S. lawmakers push to bring such transactions under national security review.

AstraZeneca obesity pill moves to Phase III after nearly 12% weight loss in mid-stage trials

AstraZeneca unveiled full results from two mid-stage trials of its experimental oral obesity drug elecoglipron on Monday at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, revealing that the once-daily pill produced an average body weight reduction of…